Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoVasc-ICH2
2025-523435-18-00Phase 3Authorised
- Sponsor
- Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International
- Start
- Jul 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in intracerebral hemorrhage (ICH) and major adverse cardiac events (MACE) comparing Colchicine with Placebo (2 arms). Primary endpoints: Hierarchical composite endpoint, Time to first stroke and 4 more. Planned start Jul 2026; status: authorised.
02
Drugs
colchicine
03
Conditions
intracerebral hemorrhage (ICH)major adverse cardiac events (MACE)
Beyond the preview
Go deeper on 2025-523435-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523435-18-00.